Revitalization of Damaged Skin Due to Chronic Skin Diseases
1 other identifier
interventional
200
2 countries
2
Brief Summary
Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture of natural peptides and herbs. the main aim is to restore the normal skin appearance for the patient and control the episodes of flare.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for early_phase_1
Started May 2018
Shorter than P25 for early_phase_1
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 7, 2017
CompletedFirst Posted
Study publicly available on registry
April 2, 2018
CompletedStudy Start
First participant enrolled
May 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2019
CompletedApril 2, 2018
November 1, 2017
6 months
October 7, 2017
March 26, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Regeneration of the damaged skin lesion
Complete regeneration of the affected skin lesions from the skin disease.
6 - 9 months
Secondary Outcomes (1)
Flare control
1-3 months
Study Arms (1)
internvention of Chrinic skin conditions
EXPERIMENTALAll cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
Interventions
Topical application of the ACE CSD 4 times daily.
Eligibility Criteria
You may qualify if:
- Chronic skin condition lasts for more than 1 year.
- tried traditional treatment with limited or without effect.
- not on steroids for at least 6 weeks.
You may not qualify if:
- patients on steroid.
- patients intolerable to protein or allergic to proteins
- during pregnancy or lactation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
ACE cells Lab Europe Doo
Belgrade, 11000, Serbia
ACE Cells Lab Limited
Nottingham, Nottinghamshire, NG90 6BH, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dr. Diana Diana, MSc Dermatology
ACE cells Lab europe DOO
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 7, 2017
First Posted
April 2, 2018
Study Start
May 1, 2018
Primary Completion
November 1, 2018
Study Completion
January 1, 2019
Last Updated
April 2, 2018
Record last verified: 2017-11
Data Sharing
- IPD Sharing
- Will not share